OctoPlus Wins new Drug Delivery Evaluation Contract for Two Compounds
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
As part of the Company's strategic focus on developing controlled release formulations for clients, OctoPlus N.V. (OctoPlus) announces that it has signed a new drug delivery technology evaluation contract for two compounds with a European biotech company. This is the eighth client for which OctoPlus will work on a controlled release formulation.
In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing.
Under this contract, OctoPlus will evaluate the feasibility of two controlled release formulations that combine the active ingredients of the client with OctoPlus' proprietary drug delivery technology. If the evaluations are successful, the contract may progress to a full process development, manufacturing and licensing agreement.
In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing.
Under this contract, OctoPlus will evaluate the feasibility of two controlled release formulations that combine the active ingredients of the client with OctoPlus' proprietary drug delivery technology. If the evaluations are successful, the contract may progress to a full process development, manufacturing and licensing agreement.
